Dr. Reddy's Laboratories has launched Repatha (evolocumab) 140 mg/ml, the first and only PCSK9 Inhibitor available in India, approved by the Drug Controller General India (DCGI).
Repatha (evolocumab) is a patented product of Amgen global, indicated for the treatment of adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia. It is used as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
